9[11]Jatoi A,Hillman SH,Stella P,et al.Should Elderly Non-Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group[J].Journal of Clinical Oncology,2005,23 (36):9113-9119
6[1]Parente B,Barroso A,Condes,et al.A prospective study of gemeitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer:toxicity of a three-versus a four-week schedule[J].Semin Oncol,2001,28:10-14
7[2]Domine M,Casado V,Estevez LG,et al.Gemcitabin and carboplatin for patients with advanced non-small cell lung cancer[J].Semin Oncol,2001,28:4-9.
8[4]Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small cell lung cancer[J].N Engl J Med,2002,346:92-98
9[5]Crino L,Cappuzzo F.Present and future treatment of advanced non-small cell lung cancer[J].Semin Oncol,2002,29:9-16
10[1]Schiller JH. Current standards of care in small-cell and nonsmall-cell lung cancer. Oncology, 2001, 61:3
3R Govindan, N Page, D Morgensztern, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database [J]. Journal of Clinical Oncology, 2006,24 (28) :4539.
4Luciani A, Bertuzzi C, Ascione G, et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer [J]. Lung Cancer,2009,66( 1 ) :94.
5C Gridelli, F Perrone, C Gallo, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer:the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase Ⅲ randomized trial[J].Journal of the National Cancer Institute,2003,95 (5) :362.
6C Gridelli, S Gigolari, C Gallo, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients phase Ⅱdata from the Muhicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial [J].Lung Cancer, 2001, 31 (2) :277.
